Meguro-ku
Meguro-ku
Meguro-ku, Tokyo, Japan30 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, nutritional disorder, obesity disorder, overnutrition, type 2 diabetes mellitus | Recruiting | Phase 3 | 2026-10-05 | NCT07684144 | |
| A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-10-05 | NCT04928846 | |
| A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | Neovascular Age-related Macular Degeneration; nAMD | Recruiting | Phase 3 | 2026-09-29 | NCT07614776 | |
| Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC | mCRPC | Active, not recruiting | Phase 3 | 2026-09-29 | NCT03395197 | |
| This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. | Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-09-25 | NCT06758401 | |
| Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer | Advanced Breast Cancer | Active, not recruiting | Phase 2 | 2026-09-18 | NCT04524000 | |
| A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM) | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, nutritional disorder, obesity disorder, overnutrition, type 2 diabetes mellitus | Active, not recruiting | Phase 2 | 2026-09-11 | NCT06660173 | |
| A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, arthritic joint disease, arthropathy, bone disorder, musculoskeletal system disorder, psoriasis, psoriatic arthritis, skin disorder, spondylitis, vertebral column disorder | Active, not recruiting | Phase 3 | 2026-09-11 | NCT04908189 | |
| Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, arthritic joint disease, arthropathy, bone disorder, musculoskeletal system disorder, psoriasis, psoriatic arthritis, skin disorder, spondylitis, vertebral column disorder | Recruiting | Phase 3 | 2026-09-09 | NCT07286058 | |
| A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, arthritic joint disease, arthropathy, bone disorder, musculoskeletal system disorder, psoriasis, psoriatic arthritis, skin disorder, spondylitis, vertebral column disorder | Recruiting | Phase 3 | 2026-09-09 | NCT06671496 | |
| Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2026-09-04 | NCT04821622 | |
| A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME | Diabetic Macular Edema (DME) | Active, not recruiting | Phase 2 / Phase 3 | 2026-08-20 | NCT06957080 | |
| A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome. | Sjogren syndrome, Skin and Connective Tissue Diseases, Stomatognathic Diseases, Xerostomia, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, dry eye syndrome, eye disorder, immune system disorder, lacrimal apparatus disorder, mouth disorder, musculoskeletal system disorder, rheumatic disorder, rheumatoid arthritis, salivary gland disorder | Active, not recruiting | Phase 3 | 2026-08-19 | NCT05985915 | |
| A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Active, not recruiting | Phase 2 | 2026-08-17 | NCT04895696 | |
| A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Phase 3 | 2026-08-14 | NCT05869903 | |
| Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial) | Behcet disease, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, Skin and Connective Tissue Diseases, Stomatognathic Diseases, anterior uveitis, antiphospholipid syndrome, autoimmune disease, blood coagulation disease, blood platelet disease, bullous pemphigoid, cardiovascular disorder, connective tissue disorder, dermatomyositis, eye disorder, hematologic disorder, hemorrhagic disease, hereditary disease, hereditary periodic fever syndrome, hereditary skin disorder, immune system disorder, mouth disorder, muscle tissue disorder, musculoskeletal system disorder, myositis disease, nervous system disorder, neuromuscular disease, panuveitis, polymyositis, purpura, skin disorder, skin vascular disease, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy, uveal disorder, uveitis, vascular disorder, vasculitis, vesiculobullous skin disease | Enrolling by invitation | Phase 1 | 2026-07-17 | NCT06723106 | |
| Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP) | Chronic Rhinosinusitis With Nasal Polyposis | Active, not recruiting | Not stated | 2026-07-13 | NCT04959448 | |
| Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome | Sjogren syndrome, Skin and Connective Tissue Diseases, Stomatognathic Diseases, Xerostomia, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, dry eye syndrome, eye disorder, immune system disorder, lacrimal apparatus disorder, mouth disorder, musculoskeletal system disorder, rheumatic disorder, rheumatoid arthritis, salivary gland disorder | Active, not recruiting | Phase 3 | 2026-06-17 | NCT05349214 | |
| A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF) | cardiovascular disorder, heart disorder, heart failure | Recruiting | Phase 2 | 2026-05-27 | NCT06991257 | |
| A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) | Sjogren syndrome, Skin and Connective Tissue Diseases, Stomatognathic Diseases, Xerostomia, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, dry eye syndrome, eye disorder, immune system disorder, lacrimal apparatus disorder, mouth disorder, musculoskeletal system disorder, rheumatic disorder, rheumatoid arthritis, salivary gland disorder | Recruiting | Phase 3 | 2026-04-28 | NCT06747949 | |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis | Fibrosis, Hemic and Lymphatic Diseases, Hypersensitivity, Delayed, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, diffuse scleroderma, immune system disorder, interstitial lung disease, lung disorder, lymphatic system disorder, lymphoproliferative syndrome, musculoskeletal system disorder, pulmonary fibrosis, respiratory system disorder, rheumatic disorder, rheumatoid arthritis, sarcoidosis, skin disorder, systemic sclerosis | Active, not recruiting | Phase 3 | 2026-04-23 | NCT06025578 | |
| A Clinical Study of the Paradise™ Renal Denervation System in Patients With Hypertension (RADIANCE-HTN DUO) | cardiovascular disorder, hypertensive disorder, vascular disorder | Active, not recruiting | Not applicable | 2026-04-15 | NCT05326230 | |
| A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome | Sjogren syndrome, Skin and Connective Tissue Diseases, Stomatognathic Diseases, Xerostomia, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, dry eye syndrome, eye disorder, immune system disorder, lacrimal apparatus disorder, mouth disorder, musculoskeletal system disorder, rheumatic disorder, rheumatoid arthritis, salivary gland disorder | Active, not recruiting | Phase 3 | 2026-04-01 | NCT05946941 | |
| Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-02-27 | NCT05581303 | |
| Amplatzer Amulet LAAO vs. NOAC | Arrhythmias, Cardiac, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, heart disorder, nervous system disorder, stroke disorder, vascular disorder | Active, not recruiting | Not applicable | 2026-02-10 | NCT04226547 |